IL-12/IL-23 inhibitors: A promising approach to the treatment of inflammatory disorders

Drugs of the Future

Volumn 33, Issue 1, 2008, Pages 49-63

  Wada, Yumiko ^a  

^a Synta Pharmaceuticals Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,2 ENE 25 OXAVITAMIN D; 3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; ABT 874; ACETYLSALICYLIC ACID; APREMILAST; CALCITRIOL; CC 10004; CILOMILAST; CNTO 1275; DANTROLENE; DEHYDROXYMETHYLEPOXYQUINOMICIN; DEXAMETHASONE; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; DILTIAZEM; E 6060; INTERLEUKIN 12; INTERLEUKIN 23; LENALIDOMIDE; PENTOXIFYLLINE; RETINOIC ACID RECEPTOR ALPHA; RO 262198; SALAZOSULFAPYRIDINE; SALBUTAMOL; STA 5326; TACROLIMUS; TAMIBAROTENE; THALIDOMIDE DERIVATIVE; THEAFLAVIN 3,3' DIGALLATE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D DERIVATIVE; ZK 156979;

ACUTE GRAFT VERSUS HOST DISEASE; ASTHMA; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COLITIS; CONTACT DERMATITIS; CYTOKINE PRODUCTION; DRUG INHIBITION; ENTERITIS; HUMAN; INFLAMMATORY DISEASE; LIMB SWELLING; LIVER CELL CARCINOMA; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MYELODYSPLASIA; OSTEOPOROSIS; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 40949139772     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.01.1158296     Document Type: Review

References (141)

1. Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3(2): 133-46.
2. Aggarwal, S., Ghilardi, N., Xie, M.H., de Sauvage, F.J., Gurney, A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003, 278(3): 1910-4.
3. Oppmann, B., Lesley, R., Blom, B. et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13(5): 715-25.
4. Langrish, C.L., McKenzie, B.S., Wilson, N.J., de Waal Malefyt, R., Kastelein, R.A., Cua, D.J. IL-12 and IL-23: Master regulators of innate and adaptive immunity. Immunol Rev 2004, 202: 96-105.
5. Kikly, K., Liu, L., Na, S., Sedgwick, J.D. The IL-23/Th(17) axis: Therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006, 18(6): 670-5.
6. Cua, D.J., Sherlock, J., Chen, Y. et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421(6924): 744-8.
7. Hong, K., Chu, A., Ludviksson, B.R., Berg, E.L., Ehrhardt, R.O. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol 1999, 162(12): 7480-91.
8. Karp, C.L., Biron, C.A., Irani, D.N. Interferon beta in multiple sclerosis: Is IL-12 suppression the key? Immunol Today 2000, 21(1): 24-8.
9. Murphy, C.A., Langrish, C.L., Chen, Y. et al. Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198(12): 1951-7.
10. Segal, B.M., Dwyer, B.K., Shevach, E.M. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 1998, 187(4): 537-46.
11. Sinigaglia, F., D'Ambrosio, D., Panina-Bordignon, P., Rogge, L. Regulation of the IL-12/IL-12R axis: A critical step in T-helper cell differentiation and effector function. Immunol Rev 1999, 170: 65-72.
12. Tozawa, K., Hanai, H., Sugimoto, K. et al. Evidence for the critical role of interleukin-12 but not interferon-gamma in the pathogenesis of experimental colitis in mice. J Gastroenterol Hepatol 2003, 18(5): 578-87.
13. Krueger, G.G., Langley, R.G., Leonardi, C. et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007, 356(6): 580-92.
14. Mannon, P.J., Fuss, I.J., Mayer, L. et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004, 351(20): 2069-79.
15. Hasko, G., Szabo, C. IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: Regulation of T helper 1/T helper 2 responses. Br J Pharmacol 1999, 127(6): 1295-304.
16. Hue, S., Ahern, P., Buonocore, S. et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 2006, 203(11): 2473-83.
17. Yen, D., Cheung, J., Scheerens, H. et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006, 116(5): 1310-6.
18. Hunter, C.A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005, 5(7): 521-31.
19. Chen, Y., Langrish, C.L., McKenzie, B. et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006, 116(5): 1317-26.
20. Langrish, C.L., Chen, Y., Blumenschein, W.M. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201(2): 233-40.
21. Zheng, Y., Danilenko, D.M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., Ouyang, W. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445(7128): 648-51.
22. Chan, J.R., Blumenschein, W., Murphy, E. et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006, 203(12): 2577-87.
23. Lee, E., Trepicchio, W.L., Oestreicher, J.L. et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004, 199(1): 125-30.
24. Chamian, F., Lowes, M.A., Lin, S.L. et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci USA 2005, 102(6): 2075-80.
25. Gottlieb, A.B., Chamian, F., Masud, S. et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005, 175(4): 2721-9.
26. Vaknin-Dembinsky, A., Balashov, K. Weiner, H.L. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol 2006, 176(12): 7768-74.
27. Matusevicius, D., Kivisakk, P., He, B., Kostulas, N., Ozenci, V., Fredrikson, S., Link, H. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999, 5(2): 101-4.
28. Fuss, I. J., Becker, C., Yang, Z. et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 2006, 12(1): 9-15.
29. Kim, H.R., Cho, M.L., Kim, K.W. et al. Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB- and p38 MAPK-dependent signalling pathways. Rheumatology (Oxford) 2007, 46(1): 57-64.
30. Cargill, M., Schrodi, S.J., Chang, M. et al. A large-scale genetic association study confirms IL 12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007, 80(2): 273-90.
31. Duerr, R.H., Taylor, K.D., Brant, S.R. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314(5804): 1461-3.
32. Sanjabi, S., Hoffmann, A., Liou, H.C., Baltimore, D., Smale, S.T. Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. Proc Natl Acad Sci USA 2000, 97(23): 12705-10.
33. Grumont, R., Hochrein, H., O'Keeffe, M. et al. c-Rel regulates interleukin 12 p70 expression in CD8(+) dendritic cells by specifically inducing p35 gene transcription. J Exp Med 2001, 194(8): 1021-32.
34. Carmody, R.J., Ruan, Q., Liou, H.C., Chen, Y.H. Essential roles of c-Rel in TLR-induced IL-23 p19 gene expression in dendritic cells. J Immunol 2007, 178(1): 186-91.
35. Antonsson, A., Hughes, K., Edin, S., Grundstrom, T. Regulation of c-Rel nuclear localization by binding of Ca2+/calmodulin. Mol Cell Biol 2003, 23(4): 1418-27.
36. Huang, F.P., Niedbala, W., Wei, X.Q. et al. Nitric oxide regulates Th1 cell development through the inhibition of IL-12 synthesis by macrophages. Eur J Immunol 1998, 28(12): 4062-70.
37. Khan, N., Rahim, S.S., Boddupalli, C.S. et al. Hydrogen peroxide inhibits IL-12 p40 induction in macrophages by inhibiting c-rel translocation to the nucleus through activation of calmodulin protein. Blood 2006, 107(4): 1513-20.
38. Boddupalli, C.S., Ghosh, S., Rahim, S.S. et al. Nitric oxide inhibits interleukin-12 p40 through p38 MAPK-mediated regulation of calmodulin and c-rel. Free Radic Biol Med 2007, 42(5): 686-97.
39. Utsugi, M., Dobashi, K., Ishizuka, T. et al. c-Jun N-terminal kinase negatively regulates lipopolysaccharide-induced IL-12 production in human macrophages: Role of mitogen-activated protein kinase in glutathione redox regulation of IL-12 production. J Immunol 2003, 171(2): 628-35.
40. Feng, G.J., Goodridge, H.S., Harnett, M.M. et al. Extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases differentially regulate the lipopolysaccharide-mediated induction of inducible nitric oxide synthase and IL-12 in macrophages: Leishmania phosphoglycans subvert macrophage IL-12 production by targeting ERK MAP kinase. J Immunol 1999, 163(12): 6403-12.
41. Aicher, A., Shu, G.L., Magaletti, D. et al. Differential role for p38 mitogen-activated protein kinase in regulating CD40-inducedgene expression in dendritic cells and B cells. J Immunol 1999, 163(11): 5786-95.
42. Marriott, J.B., Clarke, I.A., Dalgleish, A.G. Inhibition of p38 MAP kinase during cellular activation results in IFN-gamma-dependent augmentation of IL-12 production by human monocytes/macrophages. Clin Exp Immunol 2001, 125(1): 64-70.
43. Salmon, R.A., Guo, X., Teh, H.S., Schrader, J.W. The p38 mitogen-activated protein kinases can have opposing roles in the antigen-dependent or endotoxin-stimulated production of IL-12 and IFN-gamma. Eur J Immunol 2001, 31(11): 3218-27.
44. Ma, W., Gee, K., Lim, W. et al. Dexamethasone inhibits IL-12p40 production in lipopolysaccharide-stimulated human monocytic cells by down-regulating the activity of c-Jun N-terminal kinase, the activation protein-1, and NF-kappa B transcription factors. J Immunol 2004, 172(1): 318-30.
45. Nakahara, T., Uchi, H., Urabe, K., Chen, Q., Furue, M., Moroi, Y. Role of c-Jun N-terminal kinase on lipopolysaccharide induced maturation of human monocyte-derived dendritic cells. Int Immunol 2004, 16(12): 1701-9.
46. Puig-Kroger, A., Relloso, M., Femandez-Capetillo, O. et al. Extracellular signal-regulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells. Blood 2001, 98(7): 2175-82.
47. Yang, C.S., Lee, J.S., Jung, S.B. et al. Differential regulation of interleukin-12 and tumour necrosis factor-alpha by phosphatidylinositol 3-kinase and ERK 1/2 pathways during Mycobacterium tuberculosis infection. Clin Exp Immunol 2006, 143(1): 150-60.
48. Harris, S. G., Padilla, J., Koumas, L., Ray, D., Phipps, R. P. Prostaglandins as modulators of immunity. Trends Immunol 2002, 23(3): 144-50.
49. Kalinski, P., Vieira, P.L., Schuitemaker, J.H., de Jong, E.C., Kapsenberg, M.L. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 2001, 97(11): 3466-9.
50. van der Pouw Kraan, T.C., Boeije, L.C., Smeenk, R.J., Wijdenes, J., Aarden, L.A. Prostaglandine is a potent inhibitor of human interleukin 12 production. J Exp Med 1995, 181(2): 775-9.
51. Kimball, A.B., Gordon, K.B., Valdes, J.M. Safety and efficacy of the fully human IL-12/-23 monoclonal antibody, ABT-874, in the treatment of moderate to severe plaque psoriasis: Results from a phase II trial. J Invest Dermatol [68th Annu Meet Soc Invest Dermatol (May 9-12, Los Angeles) 2007] 2007, 127(Suppl. 1): Abst 321.
52. Toichi, E., Torres, G., McCormick, T.S. et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006, 177(7): 4917-26.
53. Wada, Y., Lu, R., Zhou, D. et al. Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood 2007, 109(3): 1156-64.
54. Wada, Y. Identification of pharmacodynamic biomarkers in a clinical trial to establish a compound's biologic effect. 11th Annu World Congr Drug Discov (Aug 7-10, Boston) 2006.
55. Matsumoto, N., Ariga, A., To-e, S. et al. Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett 2000, 10(9): 865-9.
56. Ariga, A., Namekawa, J., Matsumoto, N., Inoue, J., Umezawa, K. Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J Biol Chem 2002, 277(27): 24625-30.
57. Suzuki, E., Umezawa, K. Inhibition of macrophage activation and phagocytosis by a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin. Biomed Pharmacother 2006, 60(9): 578-86.
58. Wakamatsu, K., Nanki, T., Miyasaka, N., Umezawa, K., Kubota, T. Effecf of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells. Arthritis Res Ther 2005, 7(6): R1348-59.
59. D'Ambrosio, D., Cippitelli, M., Cocciolo, M.G. et al. Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40gene. J Clin Invest 1998, 101(1): 252-62.
60. Lemire, J.M., Archer, D.C., Beck, L., Spiegelberg, H.L. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: Preferential inhibition of Th1 functions. J Nutr 1995, 125(6, Suppl.): 1704S-8S.
61. Yu, X.P., Bellido, T., Manolagas, S.C. Down-regulation of NF-kappa B protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1995, 92(24): 10990-4.
62. Xing, N., Maldonado, M.L., Bachman, L.A., McKean, D.J., Kumar, R., Griffin, M.D. Distinctive dendritic cell modulation by vitamin D(3) and glucocorticoid pathways. Biochem Biophys Res Commun 2002, 297(3): 645-52.
63. Cohen-Lahav, M., Douvdevani, A., Chaimovitz, C., Shany, S. The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages. J Steroid Biochem MoI Biol 2007, 103(3-5): 558-62.
64. Daniel, C., Schlauch, T., Zugel, U. et al. 22-Ene-25-oxa-vitamin D: A new vitamin D analogue with profound immunosuppressive capacities. Eur J Clin Invest 2005, 35(5): 343-9.
65. Daniel, C., Radeke, H.H., Sartory, N.A. et al. The new low calcemic vitamin D analog 22-ene-25-oxa-vitamin D prominently ameliorates T helper cell type 1-mediated colitis in mice. J Pharmacol Exp Ther 2006, 319(2): 622-31.
66. Daniel, C., Radeke, H.H., Zuegel, U., Stein, J.M. 22-Ene-25-oxa- vitamin D (ZK156979) affects the IL-23/IL-17-/IL-6 axis to treat Th1-mediated experimental colitis in mice. Gastroenterology [Dig Dis Week (May 19-24, Washington, D.C) 2007] 2007, 132(4, Suppl. 2): Abst S1594.
67. Gregori, S., Giarratana, N., Smiroldo, S., Uskokovic, M., Adorini, L. A 1α,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002, 51(5): 1367-74.
68. Blotta, M.H., DeKruyff, R.H., Umetsu, D.T. Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. J Immunol 1997, 158(12): 5589-95.
69. DeKruyff, R.H., Fang, Y., Umetsu, D.T. Corticosteroids enhance the capacity of macrophages to induce Th2 cytokine synthesis in CD4+ lymphocytes by inhibiting IL-12 production. J Immunol 1998, 160(5): 2231-7.
70. Crinelli, R., Antonelli, A., Bianchi, M., Gentilini, L., Scaramucci, S., Magnani, M. Selective inhibition of NF-kB activation and TNF-alpha production in macrophages by red blood cell-mediated delivery of dexamethasone. Blood Cells Mol Dis 2000, 26(3): 211-22.
71. Almawi, W.Y., Melemedjian, O.K. Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids. J MoI Endocrinol 2002, 28(2): 69-78.
72. Du, C., Khalil, M.W., Sriram, S. Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. J Immunol 2001, 167(12): 7094-101.
73. Xu, J., Drew, P.D. 9-Cis-retinoic acid suppresses inflammatory responses of microglia and astrocytes. J Neuroimmunol 2006, 171(1-2): 135-44.
74. Na, S.Y., Kang, B.Y., Chung, S.W. et al. Retinoids inhibit interleukin-12 production In macrophages through physical associations of retinoid X receptor and NFkappaB. J Biol Chem 1999, 274(12): 7674-80.
75. Mehta, K. Retinoids as regulators of gene transcription. J Biol Regul Homeost Agents 2003, 17(1): 1-12.
76. Wang, X., Allen, C., Ballow, M. Retinole acid enhances the production of IL-10 while reducing the synthesis of IL-12 and TNF-alpha from LPS-stimulated monocytes/macrophages. J Clin Immunol 2007, 27(2): 193-200.
77. Yoshimura, H., Kikuchi, K., Hibi, S. et al. Discovery of novel and potent retinoic acid receptor alpha agonists: Syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole derivatives. J Med Chem 2000, 43(15): 2929-37.
78. Yamauchi, T., Ishibashi, A., Shikata, K. et al. Effect of E6060 [4-{5-[7-fluoro-4-(trifluoromethyl)benzo[b]furan-2-yl]-1H-2-pyrrolyl}benzoic acid], a novel subtype-selective retinoid, on lupus-like nephritis in female (NZBxNZW)F1 mice. J Pharmacol Exp Ther 2005, 312(3): 938-44.
79. Fukasawa, H., Kagechika, H., Shudo, K. [Retinoid therapy for autoimmune diseases]. Nihon Rinsho Meneki Gakkai Kaishi 2006, 29(3): 114-26.
80. Murakami, K., Wierzba, K., Sano, M. et al. TAC-101, a benzoic acid derivative, inhibits liver metastasis of human gastrointestinal cancer and prolongs the life-span. Clin Exp Metastasis 1998, 16(4): 323-31.
81. Miyagawa, N., Homma, T., Kagechika, H., Shudo, K., Nagai, H. Effect of synthetic retinoid, TAC-101, on experimental autoimmune disease. Pharmacology 2003, 67(1): 21-31.
82. Mazzeo, D., Panina-Bordignon, P., Recalde, H., Sinigaglia, F., D'Ambrosio, D. Decreased IL-12 production and TM cell development by acetyl salicylic acid-mediated inhibition of NF-kappaB. Eur J Immunol 1998, 28(10): 3205-13.
83. Kopp, E., Ghosh, S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994, 265(5174): 956-9.
84. Yin, M.J., Yamamoto, Y., Gaynor, R.B. The anti-Inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396(6706): 77-80.
85. Wahl, C., Liptay, S., Adler, G., Schmid, R.M. Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998, 101(5): 1163-74.
86. Hasko, G., Szabo, C., Nemeth, Z.H., Deitch, E.A. Sulphasalazlne inhibits macrophage activation: Inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. Immunology 2001, 103(4): 473-8.
87. Bachetoni, A., D'Ambrosio, A., Mariani, P., Cortesini, R., Quintieri, F. Diltiazem impairs maturation and functions of human dendritic cells. Hum Immunol 2002, 63(7): 524-33.
88. D'Ambrosio, A., Bachetoni, A., Giacomini, E., Quaranta, M., Quintieri, F. Diltiazem downregulates IL-12 production by human dendritic cells. Transplant Proc 2001, 33(1-2): 236-9.
89. Fansa, I., Gol, M., Nisanoglu, V., Yavas, S., Iscan, Z., Tasdemir, O. Does diltiazem inhibit the inflammatory response in cardiopulmonary bypass? Med Sci Monit 2003, 9(4): PI30-6.
90. Severa, M., D'Ambrosio, A., Giordani, L., Quintieri, F., Coccia, E. Inhibition of interleukin-12 expression in diltiazem-treated dendritic cells through the reduction of nuclear factor-kappa B transcriptional activity. Biochem Pharmacol 2005, 69(3): 425-32.
91. Nemeth, Z.H., Hasko, G., Szabo, C., Salzman, A.L., Vizi, E.S. Calcium channel blockers and dantrolene differentially reg ulate the production of interleukin-12 and interferon-gamma in endotoxemic mice. Brain Res Bull 1998, 46(3): 257-61.
92. Hasko, G., Szabo, C., Nemeth, Z.H., Lendvai, B., Vizi, E.S. Modulation by dantrolene of endotoxin-induced interleukin-10, tumour necrosis factor-alpha and nitric oxide production in vivo and in vitro. Br J Pharmacol 1998, 124(6): 1099-106.
93. Jagetia, G.C., Aggarwal, B.B. "Spicing up" of the immune system by curcumin. J Clin Immunol 2007, 27(1): 19-35.
94. Aggarwal, S., Ichikawa, H., Takada, Y., Sandur, S.K., Shishodia, S., Aggarwal, B.B. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 2006, 69(1): 195-206.
95. Pan, M.H., Lin-Shiau, S.Y., Ho, C.T., Lin, J.H., Lin, J.K. Suppression of lipopolysaccharide-induced nuclear factor-kappaB activity by theaflavin-3,3′-digallate from black tea and other polyphenols through down-regulation of IkappaB kinase activity in macrophages. Biochem Pharmacol 2000, 59(4): 357-67.
96. Ukil, A., Maity, S., Das, P.K. Protection from experimental colitis by theaflavin-3,3′-digallate correlates with inhibition of IKK and NF-kappaB activation. Br J Pharmacol 2006, 149(1): 121-31.
97. Delgado, M., Leceta, J., Ganea, D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. J Leukoc Biol 2003, 73(1): 155-64.
98. Kodali, S., Ding, W., Huang, J., Seiffert, K., Wagner, J.A., Granstein, R.D. Vasoactive intestinal peptide modulates Langerhans cell immune function. J Immunol 2004, 173(10): 6082-8.
99. Kato, H., Ito, A., Kawanokuchi, J. et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells. Mult Scler 2004, 10(6): 651-9.
100. Delgado, M., Ganea, D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation. J Biol Chem 1999, 274(45): 31930-40.
101. Quintana, F.J., Zaltzman, R., Fernandez-Montesinos, R. et al. NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function. Ann NY Acad Sci 2006, 1070: 500-6.
102. Aste-Amezaga, M., Ma, X., Sartori, A., Trinchieri, G. Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. J Immunol 1998, 160(12): 5936-44.
103. D'Andrea, A., Aste-Amezaga, M., Valiante, N.M., Ma, X., Kubin, M., Trinchieri, G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993, 178(3): 1041-8.
104. Driessler, F., Venstrom, K., Sabat, R., Asadullah, K., Schottelius, A.J. Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: A role for p50. Clin Exp Immunol 2004, 135(1): 64-73.
105. Rahim, S.S., Khan, N., Boddupalli, C.S., Hasnain, S.E., Mukhopadhyay, S. Interleukin-10 (IL-10) mediated suppression of IL-12 production in RAW 264.7 cells also involves c-rel transcription factor. Immunology 2005, 114(3): 313-21.
106. Tajima, K., Amakawa, R., Ito, T., Miyaji, M., Takebayashi, M., Fukuhara, S. Immunomodulatory effects of cyclosporin A on human peripheral blood dendritic cell subsets. Immunology 2003, 108(3): 321-8.
107. Ma, W., Mishra, S., Gee, K. et al. Cyclosporin A and FK506 inhibit IL-12p40 production through the calmodulin/calmodulin-dependent protein kinase-activated phosphoinositide 3-kinase in lipopolysaccharide-stimulated human monocytic cells. J Biol Chem 2007, 282(18): 13351-62.
108. Barnes, P.J. Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med 1995, 152(3): 838-60.
109. Panina-Bordignon, P., Mazzeo, D., Lucia, P.D. et al. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 1997, 100(6): 1513-9.
110. Malfait, A.M., Malik, A.S., Marinova-Mutafchieva, L., Butler, D.M., Maini, R.N., Feldmann, M. The beta2-adrenergic agonist salbutamol is a potent suppressor of established collagen-induced arthritis: Mechanisms of action. J Immunol 1999, 162(10): 6278-83.
111. Moller, D.R., Wysocka, M., Greenlee, B.M. et al. Inhibition of human interleukin-12 production by pentoxifylline. Immunology 1997, 91(2): 197-203.
112. Rieckmann, P., Weber, F., Gunther, A. et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol 1996, 64(2): 193-200.
113. Billah, M.M., Cooper, N., Minnicozzi, M. et al. Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quino line carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 2002, 302(1): 127-37.
114. Moller, D.R., Wysocka, M., Greenlee, B.M. et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997, 159(10): 5157-61.
115. Bauditz, J., Wedel, S., Lochs, H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002, 50(2): 196-200.
116. Moreira, A.L., Sampaio, E.P., Zmuidzinas, A., Frindt, P., Smith, K.A., Kaplan, G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993, 177(6): 1675-80.
117. Kim, Y.S., Kim, J.S., Jung, H.C., Song, I.S. The effects of thalidomide on the stimulation of NF-kappaB activity and TNF-alpha production by lipopolysaccharide in a human colonic epithelial cell line. Mol Cells 2004, 17(2): 210-6.
118. Rowland, T.L., McHugh, S.M., Deighton, J., Ewan, P.W., Dearman, R.J., Kimber, I. Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B. Int lmmunopharmacol 2001, 1(1): 49-61.
119. Keifer, J.A., Guttridge, D.C., Ashburner, B.P., Baldwin, A.S. Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001, 276(25): 22382-7.
120. Majumdar, S., Lamothe, B., Aggarwal, B.B. Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol 2002, 168(6): 2644-51.
121. Marriott, J.B., Muller, G., Stirling, D., Dalgleish, A.G. Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opin Biol Ther 2001, 1(4): 675-82.
122. Gottlieb, A. Biological activity of CC-10004 in patients with severe plaque-type psoriasis. 64th Annu Meet Am Acad Dermatol (AAD) (March 3-7, San Francisco) 2006, Abst P34.
123. CC-10004 demonstrates activity in psoriasis. DailyDrugNews.com, May 24, 2007.
124. Corral, L.G., Haslett, P.A., Muller, G.W. et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999, 163(1): 380-6.
125. Melchert, M., List, A. The thalidomide saga. Int J Biochem Cell Biol 2007, 39(7-8): 1489-99.
126. Ferguson, G.D., Jensen-Pergakes, K., Wilkey, C. et al. Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol 2007, 27(2): 210-20.
127. Lee, S. Artemisinin, promising lead natural product for various drug developments. Mini Rev Med Chem 2007, 7(4): 411-22.
128. Noori, S., Naderi, G.A., Hassan, Z.M., Habibi, Z., Bathaie, S.Z., Hashemi, S.M. Immunosuppressive activity of a molecule isolated from Artemisia annua on DTH responses compared with cyclosporin A. Int lmmunopharmacol 2004, 4(10-11): 1301-6.
129. Zhou, W.L., Wu, J.M., Wu, Q.L. et al. A novel artemisinin derivative, 3-(12-beta-artemisininoxy) phenoxyl succinic acid (SM735), mediates immunosuppressive effects in vitro and in vivo. Acta Pharmacol Sin 2005, 26(11): 1352-8.
130. Wang, J.X., Tang, W., Shi, L.P. et al. Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation. Br J Pharmacol 2007, 150(5): 652-61.
131. Iyer, S., Kontoyiannis, D., Chevrier, D. et al. Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide. J Biol Chem 2000, 275(22): 17051-7.
132. Lazarov, M., Welihinda, A., Muhr, E., Mo, L., Buelow, R., Fong, T. RDP58, a novel anti-inflammatory peptide, inhibits multiple intracellular messenger pathways and transcription factors to block TNF-alpha, IFN-gamma, and IL12 production. Dig Dis Week (May 17-22, Orlando) 2003, Abst 770.
133. De Vry, C.G., Valdez, M. et al. Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model. J Invest Dermatol 2005, 125(3): 473-81.
134. Kuhr, C.S., Lupu, M., Little, M.T., Zellmer, E., Sale, G.E., Storb, R. RDP58 does not prevent graft-versus-host disease after dog leukocyte antigen-nonidentical canine hematopoietic cell transplantation. Transplantation 2006, 81(10): 1460-2.
135. Travis, S., Yap, L.M., Hawkey, C. et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis 2005, 11(8): 713-9.
136. Alloza, I., Baxter, A., Chen, Q., Matthiesen, R., Vandenbroeck, K. Celecoxib inhibits interleukin-12 alphabeta and beta2 folding and secretion by a novel COX2-independent mechanism involving chaperones of the endoplasmic reticulum. MoI Pharmacol 2006, 69(5): 1579-87.
137. Rausch-Fan, X., Leutmezer, F., Willheim, M. et al. Regulation of cytokine production in human peripheral blood mononuclear cells and allergen-specific Th cell clones by 1alpha,25-dihydroxyvitamin D3. Int Arch Allergy Immunol 2002, 128(1): 33-41.
138. Corral, L.G., Muller, G.W. et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Moll Med 1996, 2(4): 506-15.
139. Dubey, L., Hesong, Z. Anti-inflammatory action of diltiazem in patients with unstable angina. Postgrad Med J 2006, 82(971): 594-7.
140. Kang, B.Y., Chung, S.W., Chung, W., Im, S., Hwang, S.Y., Kim, T.S. Inhibition of interleukin-12 production in lipopolysaccharide-activated macrophages by curcumin. Eur J Pharmacol 1999, 384(2-3): 191-5.
141. Kim, G.Y., Kim, K.H., Lee, S.H. et al. Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. J Immunol 2005, 174(12): 8116-24.